Safety and Feasibility
death
All patients received at least one dose of avelumab. There were no DLTs observed from using avelumab as a single agent, but we observed it in one patient with the combined treatment. The patients in part B were treated with avelumab between days 2 and 6 after LITT.There were no unexpected AEs associated with avelumab in the patients enrolled in the trial, and no AEs led to death (Incidence of AEs and AEs suspected to be related to avelumab or LITT plus avelumab (A or LITT+A)